Improving the management of chronic myeloid leukaemia.
Until recently the therapeutic options available to patients diagnosed with chronic myeloid leukaemia hinged on their suitability for allogeneic bone marrow transplantation. With the advent of new agents targeting the specific molecular pathways involved in the disease, drug therapies may have an increasingly important role in improving outcome.
Neylon
A
A
University of Newcastle, Royal Victoria Infirmary, Newcastle NE1 4LP.
O'Brien
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000209:etiology; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl